

In a further aspect, the present disclosure provides a pharmaceutical composition comprising a compound of formula (I, II, III) or a pharmaceutically acceptable salt, tautomer, stereo-isomeric form, solvate or polymorph thereof or any of the structures provided herein together with one or more pharmaceutically acceptable excipients, diluents or carriers.

Furthermore, a compound of formula (I, II, III) or a pharmaceutically acceptable salt, solvate, tautomer, stereo-isomeric form or polymorph thereof according to the current disclosure, or a pharmaceutical composition comprising said compound of formula (I, II, III) or a pharmaceutically acceptable salt, solvate, tautomer, stereo-isomeric form or polymorph thereof can be used as a medicament.

Another aspect of the disclosure is that a compound of formula (I, II, III) or its pharmaceutically acceptable salt, solvate, tautomer, stereo-isomeric form or polymorph thereof, or said pharmaceutical composition comprising said compound of formula (I, II, III) or a pharmaceutically acceptable salt, solvate, tautomer, stereo-isomeric form or polymorph thereof can be used accordingly in the treatment of a disorder in which the modulation of TLR7 and /or TLR8 is involved preferably TLR8.

Another aspect of the disclosure is use of a compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof in the manufacture of a medicament for the treatment of viral infections, immune or inflammatory disorders.

The term "(C₁₋₃)-alkyl" or "(C₁₋₆)-alkyl" refers to a straight-chain, branched-chain or cyclic saturated aliphatic hydrocarbon containing the specified number of carbon atoms.

The term "cycloalkyl" refers to a carbocyclic ring containing the specified number of carbon atoms such as cyclo-propyl.

The term "alkoxy" refers to an alkyl (carbon and hydrogen chain) group singular bonded to oxygen (e.g. methoxy group or ethoxy group) such as C₁₋₃ alkoxy.

As used herein, any chemical formula with bonds shown only as solid lines and not as solid wedged or hashed wedged bonds, or otherwise indicated as having a particular configuration (e.g. *R*, *S*) around one or more atoms, contemplates each possible stereoisomer, or mixture of two or more stereoisomers.


The terms "stereoisomers", "stereoisomeric forms" or "stereochemically isomeric forms" hereinbefore or hereinafter are used interchangeably.

The invention includes all stereoisomers of the compounds of the invention either as a pure stereoisomer or as a mixture of two or more stereoisomers.

Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.

Claims

1. A compound of formula (I), (II) or (III) having the structure




- or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof, wherein

R_1 is C_{1-6} alkyl optionally substituted by one or more substituents independently selected from alcohol or C_{1-3} alkoxy;

R_2 is selected from hydrogen, fluorine, C_{1-3} alkyl, cyclopropyl, $-CF_3$, C_{1-3} alkoxy or nitrile.

2. A compound according to claim 1 having the structure



3. A pharmaceutical composition comprising a compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1 or any of the structures according to claim 2 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

4. A compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1 or 2 or a pharmaceutical composition according to claim 3 for use as a medicament.

5. A compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1 or 2, or a pharmaceutical composition according to claim 3 for use in the treatment of a disorder in which the modulation of TLR7 and /or TLR8 is involved, preferably TLR8.
5
6. Use of a compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1 or 2 in the manufacture of a medicament for the treatment of viral infections, immune or inflammatory disorders.
10